Paper Details

  1. Home
  2. Paper Details

Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders.

Author: GoldwaterP N

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the efficacy of a fifth dose of hepatitis B vaccine with or without interferon-alpha in non-responders and hyporesponders to the vaccine. A fifth dose of vaccine was recommended, with interferon-alpha potentially increasing seroconversion in non-responders.
Paper Details　
Original Abstract of the Article :
Adults who had received 4 x 20 micrograms doses of hepatitis B (Engerix-B) vaccine (appropriately administered) and who had failed to develop detectable anti-HBs or who had had a minimal response (< 10 IU l-1) were randomized to receive either a fifth dose of Engerix-B (20 micrograms) plus 1 million...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0264-410x(94)90116-3

データ提供：米国国立医学図書館（NLM）

The Quest for Oasis in the Desert of Hepatitis B

Hepatitis B is a serious disease, like a treacherous desert that can leave lasting scars. Vaccination is a powerful weapon against this disease, but not everyone responds effectively to the vaccine, like finding a dry well in the desert. This randomized trial explored the potential of interferon-alpha, a biological agent that helps the body fight infection, to boost the immune response to hepatitis B vaccine in non-responders and hyporesponders.

Interferon-alpha: A Potential Oasis, but Not a Guaranteed One

The study found that a fifth dose of vaccine alone was more effective than a fifth dose plus interferon-alpha in non-responders. In hyporesponders, interferon-alpha did increase the likelihood of a response, but this result was not statistically significant. This suggests that while interferon-alpha may offer a glimmer of hope, it's not a guaranteed oasis in the desert of hepatitis B. The study recommends a fifth dose of vaccine for both non-responders and hyporesponders, but further research is needed to determine the true role of interferon-alpha in this fight.

Life in the Desert: What to Consider

This research is a reminder that even the most effective tools, like vaccines, can sometimes fall short. It's important to be aware of individual responses to vaccines and to discuss any concerns with a healthcare professional. Just as a desert traveler needs to be prepared for unexpected challenges, understanding the nuances of vaccination is crucial for protecting ourselves from disease.

Dr. Camel's Conclusion

This study is a testament to the ongoing search for effective solutions to hepatitis B. While interferon-alpha did not demonstrate a clear benefit in this trial, it's a reminder that the desert of medical research is vast and constantly evolving. Future research may uncover new ways to improve the effectiveness of vaccines and protect individuals from this potentially serious disease.

Date :
  1. Date Completed 1994-08-04
  2. Date Revised 2019-07-28
Further Info :

Pubmed ID

8023548

DOI: Digital Object Identifier

10.1016/0264-410x(94)90116-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.